ArticlePharmacology research & perspectives2022

The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.

Masahiko Iwamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.